SCHEMBL8903266

SCHEMBL8903266

N=C(N)ON1C(=O)CCC1=O

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.34
TSHR P16473 1/20 0.32
PARL Q9H300 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL699757 0.78 MGLL (0.36) MGLLTSHRPARL
SCHEMBL28377582 0.74 MGLL (0.36) MGLLTSHRPARL
SCHEMBL16699304 0.73 POLB (0.31)
SCHEMBL865136 0.72 MGLL (0.40) MGLLPARL
SCHEMBL17447 0.72 MGLL (0.37) MGLLPARL
SCHEMBL15321160 0.71 MGLL (0.36) MGLLPARL
Hno SCHEMBL15321628 0.71 MGLL (0.36) MGLLPARL
Ethylene Glycol SCHEMBL5712362 0.71 MGLL (0.33) MGLLTSHR
SCHEMBL13533087 0.71 MGLL (0.32) MGLL
SCHEMBL21947419 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0785465-A1 Molecular grafting of carboxyl reactive hardeners to energetically treated polyesters to promote adhesion of layers EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1997-07-23 EP claimed
US-20170231228-A1 SURFACE TREATMENTS BOVIN NICOLAI VLADIMIROVICH (RU) 2017-08-17 US disclosed
EP-0785465-A1 Molecular grafting of carboxyl reactive hardeners to energetically treated polyesters to promote adhesion of layers EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1997-07-23 EP disclosed
EP-0535999-B1 Method for hardening gelatin EASTMAN KODAK CO (US) 1995-03-29 EP disclosed
EP-0383843-B1 METHOD AND COMPOSITION FOR HARDENING GELATIN COMPOSITIONS EASTMAN KODAK CO (US) 1994-08-10 EP disclosed
US-5236822-A METHOD AND COMPOSITION FOR HARDENING GELATIN EASTMAN KODAK COMPANY (US) 1993-08-17 US disclosed
EP-0535999-A1 Method for hardening gelatin EASTMAN KODAK COMPANY (US) 1993-04-07 EP disclosed
EP-0281146-B1 METHOD AND COMPOSITION FOR HARDENING GELATIN EASTMAN KODAK COMPANY (US) 1991-08-07 EP disclosed
EP-0383843-A1 METHOD AND COMPOSITION FOR HARDENING GELATIN COMPOSITIONS. EASTMAN KODAK CO (US) 1990-08-29 EP disclosed
WO-1990002357-A1 METHOD AND COMPOSITION FOR HARDENING GELATIN COMPOSITIONS EASTMAN KODAK COMPANY (US) 1990-03-08 WO disclosed
US-4877724-A Method and composition for hardening gelatin EASTMAN KODAK COMPANY (US) 1989-10-31 US disclosed
EP-0281146-A1 Method and composition for hardening gelatin EASTMAN KODAK COMPANY (US) 1988-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170231228-A1 SURFACE TREATMENTS PHOSPHO1, SGMS2, SGMS1 MGLL 63/4885TSHR 656/4885PARL 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.